英国 HD3 国家队列研究：单纯化疗治疗儿童和青少年霍奇金淋巴瘤的临床结局。

Clinical outcome in children and adolescents with Hodgkin lymphoma after treatment with chemotherapy alone - the results of the United Kingdom HD3 national cohort trial.

机构信息

Department of Paediatric and Adolescent Oncology, University College London Hospitals NHS Trust, London, UK.

出版信息

Eur J Cancer. 2012 Jan;48(1):108-13. doi: 10.1016/j.ejca.2011.05.029. Epub 2011 Jun 22.

DOI:10.1016/j.ejca.2011.05.029

PMID:21703849

Abstract

PURPOSE

To assess the efficacy of a standardised hybrid chemotherapy treatment programme for Hodgkin lymphoma (HL) in a national series of children and adolescents.

PATIENTS AND METHODS

The 381 assessable patients, treated between March 2000 and April 2005 in the United Kingdom Children's Cancer Study Group trial, were reviewed to evaluate overall survival (OS), disease free survival (DFS) and deaths. Protocol treatment for stages 2-4 offered a hybrid programme of ChlVbPP (chlorambucil, vinblastine, prednisolone, procarbazine) alternating with ABVcD (doxorubicin, bleomycin, vincristine, dacarbazine). Patients with stage I disease only were offered involved field radiation alone or hybrid chemotherapy.

RESULTS

With a median follow up of 5.1 years (range 0.5-8.4 years), the 5 years OS and DFS for all patients was 97% and 78%, respectively. By multivariate analysis, mediastinal and stage IV disease at presentation were the only factors that affected achieving a complete response. The 5-year DFS rate for patients with stage IV disease was 55% whilst patients with mediastinal disease had a 2-fold higher risk of an event.

CONCLUSIONS

This study demonstrated that multi-agent chemotherapy alone is insufficient treatment for patients with mediastinal and stage IV disease.

摘要

目的

评估霍奇金淋巴瘤（HL）标准化混合化疗方案在英国一系列儿童和青少年患者中的疗效。

方法

对 2000 年 3 月至 2005 年 4 月期间在英国儿童癌症研究组试验中接受治疗的 381 例可评估患者进行回顾性分析，以评估总生存率（OS）、无病生存率（DFS）和死亡情况。2-4 期患者采用 ChlVbPP（苯丁酸氮芥、长春新碱、泼尼松、丙卡巴肼）与 ABVcD（多柔比星、博来霉素、长春新碱、达卡巴嗪）交替的混合方案治疗。仅 I 期疾病患者接受受累野放疗或混合化疗。